Valeria Santini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4999859/publications.pdf

Version: 2024-02-01

282	12,161	41323	30894
papers	citations	49 h-index	102 g-index

288	288	288	9416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250.	0.2	10
2	The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. Advances in Therapy, 2022, 39, 1474-1488.	1.3	7
3	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 2022, 139, 624-629.	0.6	12
4	Targeting ineffective hematopoiesis in myelodysplastic syndromes. American Journal of Hematology, 2022, 97, 171-173.	2.0	5
5	Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: Itâ€™s more a matter of burden or more of exposure to toxic iron form?. Leukemia Research, 2022, 114, 106792.	0.4	3
6	Treatment of Lower Risk Myelodysplastic Syndromes. Hemato, 2022, 3, 153-162.	0.2	0
7	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. Journal of Clinical Medicine, 2022, 11, 27.	1.0	10
8	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435.	3.3	5
9	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	0.8	0
10	Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e874-e883.	0.2	3
11	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	3.3	9
12	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances, 2022, 6, 5132-5145.	2.5	43
13	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
14	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	0.8	80
15	Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, 2021, 35, 897-900.	3.3	12
16	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer, 2021, 127, 2015-2024.	2.0	2
17	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	0.8	127
18	Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Advances, 2021, 5, 2216-2228.	2.5	24

#	Article	IF	Citations
19	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	0.8	49
20	Advances in myelodysplastic syndrome. Current Opinion in Oncology, 2021, 33, 681-686.	1.1	6
21	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	0.6	3
22	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	13.9	335
23	Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?. Frontiers in Oncology, 2020, 10, 595838.	1.3	1
24	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	2.2	56
25	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
26	SARSâ€CoVâ€2Âin Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. HemaSphere, 2020, 4, e483.	1.2	7
27	Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances, 2020, 4, 4029-4044.	2.5	12
28	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research, 2020, 99, 106472.	0.4	4
29	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. Scientific Reports, 2020, 10, 9156.	1.6	9
30	Enasidenib: a magic bullet for myelodysplastic syndromes?. Lancet Haematology,the, 2020, 7, e275-e276.	2.2	2
31	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	3.3	14
32	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia and Lymphoma, 2020, 61, 1475-1483.	0.6	4
33	The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). Blood, 2020, 136, 45-46.	0.6	20
34	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. Blood, 2020, 136, 10-12.	0.6	6
35	Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study. Blood, 2020, 136, 13-15.	0.6	7
36	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial. Blood, 2020, 136, 53-54.	0.6	24

#	Article	IF	Citations
37	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	0.6	4
38	The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions. Blood, 2020, 136, 1-2.	0.6	9
39	Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial. Blood, 2020, 136, 38-39.	0.6	2
40	A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients. Blood, 2020, 136, 23-24.	0.6	0
41	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	0.6	0
42	Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. Haematologica, 2019, 104, e4-e8.	1.7	9
43	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia, 2019, 33, 205-216.	3.3	39
44	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	5.8	55
45	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity scoreâ€matched analysis. Cancer Medicine, 2019, 8, 7567-7576.	1.3	5
46	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2019, 25, 6976-6985.	3.2	55
47	Clinical and Genetic Profiles of Young Adult Patients with Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S347.	0.2	0
48	Outcome of MDS, MDS/MPN Patients Aged <65 Treated with Hypomethylating Agents as a Bridge to Transplant in a Single Tertiary-Care Italian Center. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S346.	0.2	0
49	Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Critical Reviews in Oncology/Hematology, 2019, 140, 1-7.	2.0	26
50	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4.	0.2	3
51	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood, 2019, 133, 1020-1030.	0.6	98
52	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	3.3	195
53	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 16-25.	2.8	15
54	How I treat MDS after hypomethylating agent failure. Blood, 2019, 133, 521-529.	0.6	61

#	Article	IF	Citations
55	Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 4243-4243.	0.6	11
56	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 841-841.	0.6	7
57	Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. Blood, 2019, 134, 2999-2999.	0.6	3
58	A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story. Blood, 2019, 134, 4256-4256.	0.6	3
59	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. Blood, 2019, 134, 3000-3000.	0.6	7
60	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	0.6	17
61	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. Blood, 2019, 134, 4273-4273.	0.6	2
62	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. Journal of Clinical Oncology, 2019, 37, e18220-e18220.	0.8	0
63	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	0.6	2
64	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 4752-4752.	0.6	0
65	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-Î± in anemic patients with low-risk MDS. Leukemia, 2018, 32, 2648-2658.	3.3	100
66	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
67	Of blood and bone: the sotatercept adventure. Lancet Haematology,the, 2018, 5, e54-e55.	2.2	3
68	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	0.6	5
69	The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 136-144.e7.	0.2	15
70	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia, 2018, 32, 413-418.	3.3	58
71	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 1765-1772.	2.5	100
72	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere, 2018, 2, e150.	1.2	91

#	Article	IF	Citations
73	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia, 2018, 32, 2546-2557.	3.3	101
74	Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29, iv96-iv110.	0.6	158
75	Does G6PD-Deficiency Related Oxidative Stress and Hemolysis Affect Erythroid Response to Erythropoietic Stimulating Agents (ESA) in Myelodysplastic Patients?. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S259.	0.2	0
76	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.4	20
77	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 923-932.	2.5	114
78	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 495-500.	0.2	1
79	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematology,the, 2018, 5, e393-e402.	2.2	44
80	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	2.7	72
81	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	0.6	57
82	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. Blood, 2018, 132, 2293-2293.	0.6	1
83	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2018, 132, 1797-1797.	0.6	5
84	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	0.6	9
85	Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. Oncotarget, 2018, 9, 10561-10571.	0.8	7
86	Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome. Blood, 2018, 132, 1829-1829.	0.6	3
87	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. Blood, 2018, 132, 4389-4389.	0.6	1
88	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology,the, 2017, 4, e127-e136.	2.2	132
89	Ironâ€chelating therapy with deferasirox in transfusionâ€dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British Journal of Haematology, 2017, 177, 741-750.	1.2	23
90	Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. Haematologica, 2017, 102, e332-e335.	1.7	2

#	Article	IF	Citations
91	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia, 2017, 31, 2449-2457.	3.3	51
92	Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E117-E119.	2.0	3
93	Pro-inflammatory proteins S100A9 and tumor necrosis factor-Î± suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica, 2017, 102, 2015-2020.	1.7	28
94	Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. Journal of Thrombosis and Haemostasis, 2017, 15, 2388-2392.	1.9	29
95	Management of Lower Risk Non-del(5q) MDS. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S35-S36.	0.2	0
96	Defeating anaemia in myelodysplastic syndromes: another step forward. Lancet Oncology, The, 2017, 18, 1290-1292.	5.1	1
97	ITACA: A new validated international erythropoietic stimulating agentâ€response score that further refines the predictive power of previous scoring systems. American Journal of Hematology, 2017, 92, 1037-1046.	2.0	20
98	First-line Therapeutic Strategies for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S31-S36.	0.2	7
99	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia Research, 2017, 63, 72-77.	0.4	14
100	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research, 2017, 52, 50-57.	0.4	25
101	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644.	2.8	15
102	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	0.8	79
103	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Supportive and Palliative Care, 2016, 6, 80-88.	0.8	16
104	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	0.8	190
105	Treatment of low-risk myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2016, 2016, 462-469.	0.9	41
106	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€“dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31
107	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. Haematologica, 2016, 101, e280-e283.	1.7	41
108	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. British Journal of Haematology, 2016, 175, 975-979.	1.2	15

#	Article	IF	Citations
109	Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia, 2016, 30, 2405-2409.	3.3	31
110	Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia, 2016, 30, 1133-1142.	3.3	56
111	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	0.6	5
112	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 109-109.	0.6	2
113	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). Blood, 2016, 128, 1638-1638.	0.6	2
114	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2011-2011.	0.6	3
115	Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2016, 128, 225-225.	0.6	2
116	Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).. Journal of Clinical Oncology, 2016, 34, 7014-7014.	0.8	0
117	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	0.8	0
118	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged â‰¥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. Blood, 2016, 128, 2818-2818.	0.6	1
119	Resistance to Azacitidine Is Determined at Cellular Level By Lower Expression of Nucleoside Metabolizing Enzymes. Blood, 2016, 128, 5129-5129.	0.6	0
120	Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 3190-3190.	0.6	0
121	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematology,the, 2015, 2, e417-e426.	2.2	64
122	On Raising the â€œDust of Bloodâ€• From Unrevealing Thrombopoiesis to Treatment of Thrombocytopenias With Thrombomimetic Drugs. Seminars in Hematology, 2015, 52, 1-3.	1.8	0
123	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome â€“ Emphasis on optimized dosing schedules and new formulations. Leukemia Research, 2015, 39, 1028-1033.	0.4	19
124	Life after hypomethylating agents in myelodysplastic syndrome. Current Opinion in Hematology, 2015, 22, 155-162.	1.2	6
125	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal, 2015, 5, e347-e347.	2.8	29
126	Anemia as the Main Manifestation of Myelodysplastic Syndromes. Seminars in Hematology, 2015, 52, 348-356.	1.8	40

#	Article	IF	Citations
127	Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs. Seminars in Hematology, 2015, 52, 38-45.	1.8	13
128	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2015, 125, 1857-1872.	3.9	151
129	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1669-1669.	0.6	14
130	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	0.6	1
131	The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 355-355.	0.6	2
132	The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 3754-3754.	0.6	2
133	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	0.6	85
134	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. Blood, 2015, 126, 91-91.	0.6	7
135	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. Blood, 2015, 126, 2099-2099.	0.6	0
136	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. Blood, 2015, 126, 1665-1665.	0.6	1
137	Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells. Blood, 2015, 126, 4753-4753.	0.6	0
138	Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target geneIL3. Epigenetics, 2014, 9, 387-395.	1.3	16
139	Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research, 2014, 38, 1381-1391.	0.4	27
140	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia, 2014, 28, 621-628.	3.3	80
141	Deferasirox for transfusionâ€dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<scp>GIMEMA MDS</scp>0306 <scp>T</scp>rial). European Journal of Haematology, 2014, 92, 527-536.	1.1	90
142	Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2014, 91, 64-73.	2.0	46
143	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, 86, 207-215.		25
144	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology, 2014, 165, 49-56.	1.2	8

#	Article	IF	Citations
145	Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica, 2014, 99, 613-619.	1.7	61
146	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii57-iii69.	0.6	108
147	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research, 2014, 38, 258-262.	0.4	5
148	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, , n/a-n/a.		21
149	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	0.6	11
150	Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 4644-4644.	0.6	0
151	Distinct DNA Methylation and Expression Profiles Underlie CMML Responsiveness to Decitabine and Uncover Novel Mechanism of Resistance. Blood, 2014, 124, 4598-4598.	0.6	0
152	Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology, 2013, 88, 231-245.	2.0	26
153	Hypomethylating agents and chemotherapy in MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 411-419.	0.7	7
154	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2013, 84B, 71-81.	0.7	7
155	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Leukemia and Lymphoma, 2013, 54, 1786-1787.	0.6	8
156	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leukemia and Lymphoma, 2013, 54, 658-661.	0.6	54
157	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica, 2013, 98, 1344-1352.	1.7	35
158	A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia, 2013, 27, 1610-1613.	3.3	31
159	Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 2013, 8, 210-219.	1.3	24
160	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood, 2013, 122, 2286-2288.	0.6	67
161	A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica, 2013, 98, 1067-1072.	1.7	120
162	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. Blood, 2013, 122, 389-389.	0.6	6

#	Article	IF	Citations
163	Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia â€" A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy. Blood, 2013, 122, 5214-5214.	0.6	3
164	A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study. Blood, 2013, 122, 745-745.	0.6	1
165	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, DÃ¼sseldorf Registry and Fism. Blood, 2013, 122, 2761-2761.	0.6	1
166	Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study. Blood, 2013, 122, 2980-2980.	0.6	0
167	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	0.6	0
168	Decitabine In Advanced Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1573-1573.	0.6	1
169	Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients. Clinical Cancer Research, 2012, 18, 3079-3089.	3.2	29
170	Outcome of therapy-related myeloid neoplasms treated with azacitidine. Journal of Hematology and Oncology, 2012, 5, 44.	6.9	49
171	Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins. Seminars in Hematology, 2012, 49, 295-303.	1.8	10
172	Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. Leukemia Research, 2012, 36, 1290-1295.	0.4	14
173	In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?. Hematology American Society of Hematology Education Program, 2012, 2012, 74-75.	0.9	10
174	The quest for the perfect MDS scoring system. Leukemia Research, 2012, 36, 125-126.	0.4	1
175	Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leukemia Research, 2012, 36, 264-270.	0.4	19
176	Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leukemia Research, 2012, 36, 607-618.	0.4	19
177	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	0.9	16
178	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	0.9	26
179	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. Blood, 2012, 120, 1702-1702.	0.6	3
180	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		

#	Article	IF	Citations
181	Deferasirox Chelation Therapy in Transfusion Dependent MDS Patients. Final Report From the Gimema MDS0306 Prospective Trial. Blood, 2012, 120, 425-425.	0.6	5
182	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood, 2012, 120, 923-923.	0.6	10
183	Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study. Blood, 2012, 120, 3808-3808.	0.6	1
184	Mechanism of Resistance to Azacitidine in Myelodisplastic Syndromes.. Blood, 2012, 120, 2810-2810.	0.6	0
185	Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry. Blood, 2012, 120, 3850-3850.	0.6	0
186	Severe Hypoxia Promotes Selection of Repopulating Progenitor CELLS in Primary MDS BONE Marrow CELL Culture. Blood, 2012, 120, 4747-4747.	0.6	0
187	ANTI-Leukemic Activity of DNA Methyltransferase Inhibitors Azacitidine and Decitabine On AML1-ETO Positive CELLS Is Evident At LOW Doses and Selectively Mediated by Epigenetic Mechanisms. Blood, 2012, 120, 4615-4615.	0.6	0
188	Quality of life and physicians' perception in myelodysplastic syndromes. American Journal of Blood Research, 2012, 2, 136-47.	0.6	37
189	In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?. Hematology American Society of Hematology Education Program, 2012, 2012, 74-5.	0.9	5
190	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. PLoS ONE, 2011, 6, e23109.	1.1	95
191	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica, 2011, 96, 1457-1461.	1.7	58
192	The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). Haematologica, 2011, 96, e23-e24.	1.7	12
193	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 2011, 35, 1164-1169.	0.4	28
194	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with secondâ€generation tyrosine kinase inhibitors. American Journal of Hematology, 2011, 86, 523-525.	2.0	7
195	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higherâ€risk myelodysplastic syndromes. Cancer, 2011, 117, 2697-2702.	2.0	169
196	Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. Leukemia Research, 2011, 35, 921-931.	0.4	13
197	Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes. Oncologist, 2011, 16, 35-42.	1.9	44
198	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	3.0	362

#	Article	IF	Citations
199	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia, 2011, 25, 1910-1913.	3.3	40
200	An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy. Blood, 2011, 118, 1023-1023.	0.6	1
201	Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal of Haematology, 2010, 85, 130-138.	1.1	111
202	Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer, 2010, 116, 1485-1494.	2.0	98
203	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. American Journal of Hematology, 2010, 85, 960-963.	2.0	13
204	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research, 2010, 34, 1576-1588.	0.4	112
205	Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion. Leukemia Research, 2010, 34, 1410-1416.	0.4	50
206	Effects of azacitidine compared with conventional care regimens in elderly (â‰¥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2010, 76, 218-227.	2.0	108
207	Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 562-569.	0.8	886
208	Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs. Blood, 2010, 116, 1856-1856.	0.6	5
209	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. Blood, 2010, 116, 2293-2293.	0.6	2
210	Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation. Blood, 2010, 116, 606-606.	0.6	1
211	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	0.6	0
212	Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial. Blood, 2010, 116, 2928-2928.	0.6	0
213	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. Blood, 2010, 116, 4250-4250.	0.6	0
214	Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk. Blood, 2010, 116, 4031-4031.	0.6	1
215	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2009, 15, 5002-5007.	3.2	103
216	Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Review of Hematology, 2009, 2, 121-127.	1.0	12

#	Article	IF	Citations
217	C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique. Leukemia Research, 2009, 33, S32.	0.4	0
218	P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome. Leukemia Research, 2009, 33, S103.	0.4	0
219	P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program. Leukemia Research, 2009, 33, S127.	0.4	0
220	P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities. Leukemia Research, 2009, 33, S127-S128.	0.4	0
221	P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC). Leukemia Research, 2009, 33, S133.	0.4	0
222	P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Leukemia Research, 2009, 33, S133-S134.	0.4	0
223	P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes. Leukemia Research, 2009, 33, S139-S140.	0.4	0
224	Azacitidine in lower-risk myelodysplastic syndromes. Leukemia Research, 2009, 33, S22-S26.	0.4	12
225	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, The, 2009, 10, 223-232.	5.1	2,404
226	Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.. Blood, 2009, 114, 1755-1755.	0.6	10
227	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	0.6	3
228	Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.. Blood, 2009, 114, 3822-3822.	0.6	17
229	Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene, 2008, 27, 1767-1778.	2.6	44
230	The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British Journal of Haematology, 2008, 141, 814-819.	1.2	40
231	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	1.7	146
232	Treatment Options in Myelodysplastic Syndromes: A New Frontier. Journal of Chemotherapy, 2008, 20, 291-296.	0.7	3
233	Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).. Blood, 2008, 112, 1653-1653.	0.6	4
234	5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.. Blood, 2008, 112, 1947-1947.	0.6	2

#	Article	IF	Citations
235	The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS). Blood, 2008, 112, 227-227.	0.6	20
236	Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR). Blood, 2008, 112, 3636-3636.	0.6	5
237	Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome. Blood, 2008, 112, 2363-2363.	0.6	0
238	5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program. Blood, 2008, 112, 2680-2680.	0.6	0
239	5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. Blood, 2008, 112, 3648-3648.	0.6	1
240	Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application. Current Drug Metabolism, 2007, 8, 383-394.	0.7	126
241	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood, 2007, 110, 4620-4621.	0.6	11
242	Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells:â€‰ Inside the Mechanism of Imatinib Resistance. Journal of Proteome Research, 2007, 6, 367-375.	1.8	28
243	A selective activity of DNMTi decitabine on AML1ETO positive cells?. Leukemia Research, 2007, 31, 741-742.	0.4	1
244	The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. British Journal of Haematology, 2006, 135, 653-659.	1.2	8
245	Hemolymphangiomatosis of the Spleen. Journal of Computer Assisted Tomography, 2005, 29, 831-833.	0.5	2
246	Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Annals of Hematology, 2005, 84, 54-60.	0.8	26
247	Azacitidine in Myelodysplastic Syndromes. Drugs, 2005, 65, 1790-1791.	4.9	0
248	No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?. Leukemia and Lymphoma, 2004, 45, 1361-1364.	0.6	3
249	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leukemia Research, 2004, 28, 367-372.	0.4	46
250	In vitro antileukemic effect of a new anthracycline analogue, MEN 11079. Leukemia Research, 2003, 27, 1125-1134.	0.4	5
251	Dependence of leukemic cell autofluorescence patterns on the degree of differentiation. Photochemical and Photobiological Sciences, 2003, 2, 981.	1.6	16
252	The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal. Blood, 2003, 101, 4615-4622.	0.6	20

#	Article	IF	Citations
253	Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Research, 2003, 63, 8955-61.	0.4	39
254	Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica, 2002, 87, 322-3.	1.7	10
255	Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647. Haematologica, 2002, 87, 1242-7.	1.7	4
256	Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications. Annals of Internal Medicine, 2001, 134, 573.	2.0	351
257	Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opinion on Pharmacotherapy, 2001, 2, 479-489.	0.9	47
258	Homoharringtonine. Cancer, 2001, 92, 1591-1605.	2.0	177
259	Searching for the Magic Bullet Against Cancer: The Butyrate Saga. Leukemia and Lymphoma, 2001, 42, 275-289.	0.6	26
260	Sequential Cis-Platinum and Fludarabine with or without Arabinosyl Cytosine in Patients Failing Prior Fludarabine Therapy for Chronic Lymphocytic Leukemia: A Phase II Study. Leukemia and Lymphoma, 1999, 36, 57-65.	0.6	33
261	Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. European Journal of Pharmaceutical Sciences, 1999, 7, 93-106.	1.9	22
262	Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclines. Advances in Experimental Medicine and Biology, 1999, 457, 89-94.	0.8	0
263	Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells In Vitro. Advances in Experimental Medicine and Biology, 1999, 457, 473-476.	0.8	2
264	Butyrateâ€stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology, 1998, 101, 529-538.	1.2	20
265	DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION?. British Journal of Haematology, 1998, 102, 1124-1138.	1.2	23
266	Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. British Journal of Haematology, 1998, 102, 1335-1337.	1.2	17
267	Proliferation Signaling and Activation of Shc, p21Ras, and Myc Via Tyrosine 764 of Human Granulocyte Colony-Stimulating Factor Receptor. Blood, 1998, 91, 1924-1933.	0.6	60
268	Proliferation Signaling and Activation of Shc, p21Ras, and Myc Via Tyrosine 764 of Human Granulocyte Colony-Stimulating Factor Receptor. Blood, 1998, 91, 1924-1933.	0.6	2
269	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes and Cancer, 1997, 19, 250-255.	1.5	15
270	Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: Direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leukemia Research, 1996, 20, 37-45.	0.4	20

#	Article	IF	Citations
271	Somatostatin and its cyclic octapeptide analog SMS 201â€“995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. Leukemia Research, 1995, 19, 707-712.	0.4	17
272	Functional and structural interactions between osteoblastic and preosteoclastic cells in vitro. Cell and Tissue Research, 1995, 281, 33-42.	1.5	22
273	Autonomous Proliferation of Leukemic Cells in Vitro as a Determinant of Prognosis in Adult Acute Myeloid Leukemia. New England Journal of Medicine, 1993, 328, 614-619.	13.9	168
274	Effect of (dl)-5-Methyltetrahydrofolate on Acute Non-Lymphocytic Leukemia Cells in Primary Culture. Journal of Chemotherapy, 1991, 3, 255-259.	0.7	1
275	Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid. Leukemia Research, 1991, 15, 341-350.	0.4	29
276	Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. British Journal of Haematology, 1991, 79, 382-389.	1.2	21
277	Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): Assessment in vitro after stimulation with colony stimulating factors (CSFs). Leukemia Research, 1990, 14, 377-380.	0.4	22
278	In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay. Hematological Oncology, 1989, 7, 243-253.	0.8	23
279	In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. Hematological Oncology, 1989, 7, 287-293.	0.8	39
280	Induction of Differentiation of HL-60 Cells Along the Monocytic Pathway by 5-Methyltetrahydrofolate. Journal of Chemotherapy, 1989, 1, 359-364.	0.7	2
281	Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium. Experientia, 1988, 44, 903-906.	1.2	0
282	Proliferation and cell loss of human leukemic cell subpopulations in liquid culture. Experientia, 1988, 44, 245-247.	1.2	2